drug_type
RELEVANT_DRUG
intervention_type
Cell therapy (CAR T cells)
drug_description
Autologous, gene-modified T cells engineered to express a bispecific chimeric antigen receptor targeting BCMA (TNFRSF17) and GPRC5D on myeloma cells; CAR engagement triggers CD3ζ/costimulatory signaling to drive T-cell proliferation, cytokine release, and cytotoxic killing, aiming to reduce antigen escape and tumor heterogeneity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a bispecific CAR that recognizes BCMA and GPRC5D on myeloma cells. Antigen binding activates CD3ζ and costimulatory signaling, driving T‑cell proliferation, cytokine release, and cytotoxic killing of target cells, with dual targeting intended to limit antigen escape and address tumor heterogeneity.
drug_name
Anti-BCMA–GPRC5D CAR-T cells
nct_id_drug_ref
NCT06515262